BUZZ-计划重新提交肌肉失调药物申请后，Scholar Rock股价上涨

路透中文

Mar 03

BUZZ-计划重新提交肌肉失调药物申请后，<a href="https://laohu8.com/S/SRRK">Scholar Rock</a>股价上涨

3月3日 - ** 药物开发商Scholar Rock SRRK.O股价盘前上涨6.2%至46.16美元

** SRRK 在其财报发布 (link) 中称，公司计划重新提交其实验性药物 apitegromab 的上市申请，以治疗脊髓性肌萎缩症 $(SMA)$ 这种肌肉疾病。

** 公司称，此举是在与美国 FDA 和康泰伦特印第安纳州工厂会面后做出的，会面后监管机构认为无需采取进一步行动

** Apitegromab 此前在美国未获 (link) 批准上市，原因是药品监管机构在对诺和诺德NOVOb.CO拥有的康泰伦特印第安纳州灌装-成品工厂进行例行检查时发现了问题。

** SRRK 依靠 apitegromab 来推动公司的增长和盈利能力

** 该药物还在接受肥胖症肌肉保存试验

** 截至上次收盘，SRRK股价年累计下跌1.3%。

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616638323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616638323\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616638323?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-03 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616638323","market":"us","top_or_hot":-1,"title":"BUZZ-计划重新提交肌肉失调药物申请后，Scholar Rock股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-计划重新提交肌肉失调药物申请后，<a href=\"https://laohu8.com/S/SRRK\">Scholar Rock</a>股价上涨</title></head><body><p>\n<span>3月3日</span><span> - </span>** 药物开发商Scholar Rock <span>SRRK.O</span>股价盘前上涨6.2%至46.16美元</p><p>** SRRK 在其财报发布 (<span>link</span>) 中称，公司计划重新提交其实验性药物 apitegromab 的上市申请，以治疗脊髓性肌萎缩症 <a href=\"https://laohu8.com/S/SMA\">$(SMA)$</a> 这种肌肉疾病。</p><p>** 公司称，此举是在与美国 FDA 和康泰伦特印第安纳州工厂会面后做出的，会面后监管机构认为无需采取进一步行动</p><p>** Apitegromab 此前在美国未获 (<span>link</span>) 批准上市，原因是药品监管机构在对<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a><span>NOVOb.CO</span>拥有的康泰伦特印第安纳州灌装-成品工厂进行例行检查时发现了问题。</p><p>** SRRK 依靠 apitegromab 来推动公司的增长和盈利能力</p><p>** 该药物还在接受肥胖症肌肉保存试验</p><p>** 截至上次收盘，SRRK股价年累计下跌1.3%。 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-计划重新提交肌肉失调药物申请后，Scholar Rock股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-计划重新提交肌肉失调药物申请后，Scholar Rock股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-03 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-计划重新提交肌肉失调药物申请后，<a href=\"https://laohu8.com/S/SRRK\">Scholar Rock</a>股价上涨</title></head><body><p>\n<span>3月3日</span><span> - </span>** 药物开发商Scholar Rock <span>SRRK.O</span>股价盘前上涨6.2%至46.16美元</p><p>** SRRK 在其财报发布 (<span>link</span>) 中称，公司计划重新提交其实验性药物 apitegromab 的上市申请，以治疗脊髓性肌萎缩症 <a href=\"https://laohu8.com/S/SMA\">$(SMA)$</a> 这种肌肉疾病。</p><p>** 公司称，此举是在与美国 FDA 和康泰伦特印第安纳州工厂会面后做出的，会面后监管机构认为无需采取进一步行动</p><p>** Apitegromab 此前在美国未获 (<span>link</span>) 批准上市，原因是药品监管机构在对<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a><span>NOVOb.CO</span>拥有的康泰伦特印第安纳州灌装-成品工厂进行例行检查时发现了问题。</p><p>** SRRK 依靠 apitegromab 来推动公司的增长和盈利能力</p><p>** 该药物还在接受肥胖症肌肉保存试验</p><p>** 截至上次收盘，SRRK股价年累计下跌1.3%。 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4S3ZR19K:1","article_id":"2616638323","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616638323","pubTimestamp":1772545002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"3月3日 - ** 药物开发商Scholar Rock SRRK.O股价盘前上涨6.2%至46.16美元** SRRK 在其财报发布  中称，公司计划重新提交其实验性药物 apitegromab 的上市申请，以治疗脊髓性肌萎缩症  这种肌肉疾病。** SRRK 依靠 apitegromab 来推动公司的增长和盈利能力** 该药物还在接受肥胖症肌肉保存试验** 截至上次收盘，SRRK股价年累计下跌1.3%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","SRRK":"Scholar Rock Holding Corp"},"translate_title":"BUZZ-Scholar Rock Stock Rises After Planning to Resubmit Muscle Disorder Drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":0.9},"content_text":"BUZZ-计划重新提交肌肉失调药物申请后，Scholar Rock股价上涨\n3月3日 - ** 药物开发商Scholar Rock SRRK.O股价盘前上涨6.2%至46.16美元** SRRK 在其财报发布 (link) 中称，公司计划重新提交其实验性药物 apitegromab 的上市申请，以治疗脊髓性肌萎缩症 $(SMA)$ 这种肌肉疾病。** 公司称，此举是在与美国 FDA 和康泰伦特印第安纳州工厂会面后做出的，会面后监管机构认为无需采取进一步行动** Apitegromab 此前在美国未获 (link) 批准上市，原因是药品监管机构在对诺和诺德NOVOb.CO拥有的康泰伦特印第安纳州灌装-成品工厂进行例行检查时发现了问题。** SRRK 依靠 apitegromab 来推动公司的增长和盈利能力** 该药物还在接受肥胖症肌肉保存试验** 截至上次收盘，SRRK股价年累计下跌1.3%。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}